Everence Capital Management’s AbbVie ABBV Stock Holding History

Everence Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.6M	Hold	53,171	–	–	0.71%	21
2025 Q4	$12.1M	Hold	53,171	–	–	0.72%	20
2025 Q3	$12.3M	Hold	53,171	–	–	0.74%	22
2025 Q2	$9.87M	Hold	53,171	–	–	0.64%	24
2025 Q1	$11.1M	Hold	53,171	–	–	0.76%	19
2024 Q4	$9.45M	Buy	53,171 +15,550	+41%	+$2.86M	0.61%	27
2024 Q3	$7.43M	Hold	37,621	–	–	0.47%	34
2024 Q2	$6.12K	Hold	37,621	–	–	0.42%	41
2024 Q1	$6.85K	Hold	37,621	–	–	0.45%	38
2023 Q4	$5.83M	Sell	37,621 -3,960	-10%	-$577K	0.42%	38
2023 Q3	$6.2K	Sell	41,581 -2,600	-6%	-$382K	0.48%	34
2023 Q2	$6.09M	Hold	44,181	–	–	0.5%	31
2023 Q1	$7.04K	Hold	44,181	–	–	0.58%	29
2022 Q4	$7.14K	Buy	44,181 +3,844	+10%	+$589K	0.62%	28
2022 Q3	$5.41M	Buy	40,337 +2,240	+6%	+$321K	0.5%	34
2022 Q2	$5.83M	Buy	38,097 +5,520	+17%	+$843K	0.52%	33
2022 Q1	$5.28M	Buy	32,577 +7,540	+30%	+$1.1M	0.4%	46
2021 Q4	$3.39M	Sell	25,037 -14,780	-37%	-$1.75M	0.25%	68
2021 Q3	$4.29M	Buy	39,817 +40	+0.1%	+$4.57K	0.35%	50
2021 Q2	$4.48M	Hold	39,777	–	–	0.37%	50
2021 Q1	$4.3M	Hold	39,777	–	–	0.39%	44
2020 Q4	$4.26M	Sell	39,777 -3,210	-7%	-$308K	0.42%	42
2020 Q3	$3.77M	Buy	42,987 +2,720	+7%	+$256K	0.41%	44
2020 Q2	$3.73M	Buy	40,267 +6,148	+18%	+$541K	0.44%	39
2020 Q1	$2.6M	Hold	34,119	–	–	0.37%	49
2019 Q4	$3.02M	Sell	34,119 -2,281	-6%	-$189K	0.45%	44
2019 Q3	$2.76M	Hold	36,400	–	–	0.45%	45
2019 Q2	$2.65M	Hold	36,400	–	–	0.44%	47
2019 Q1	$2.93M	Sell	36,400 -6,242	-15%	-$511K	0.51%	40
2018 Q4	$3.93M	Hold	42,642	–	–	0.91%	20
2018 Q3	$4.03M	Hold	42,642	–	–	0.8%	21
2018 Q2	$3.95M	Hold	42,642	–	–	0.84%	19
2018 Q1	$4.04M	Hold	42,642	–	–	0.89%	18
2017 Q4	$4.12M	Buy	42,642 +2,668	+7%	+$251K	0.9%	19
2017 Q3	$3.55M	Hold	39,974	–	–	0.81%	25
2017 Q2	$2.9M	Hold	39,974	–	–	0.71%	31
2017 Q1	$2.6M	Hold	39,974	–	–	0.68%	33
2016 Q4	$2.5M	Sell	39,974 -3,439	-8%	-$210K	0.72%	29
2016 Q3	$2.74M	Hold	43,413	–	–	0.81%	25
2016 Q2	$2.69M	Buy	43,413 +2,310	+6%	+$141K	0.82%	27
2016 Q1	$2.35M	Hold	41,103	–	–	0.73%	33
2015 Q4	$2.44M	Hold	41,103	–	–	0.79%	31
2015 Q3	$2.24M	Buy	41,103 +4,587	+13%	+$299K	0.77%	32
2015 Q2	$2.45M	Sell	36,516 -2,000	-5%	-$131K	0.79%	32
2015 Q1	$2.33M	Hold	38,516	–	–	0.78%	34
2014 Q4	$2.52M	Buy	38,516 +2,564	+7%	+$162K	0.86%	25
2014 Q3	$1.99M	Hold	35,952	–	–	0.73%	34
2014 Q2	$2.03M	Hold	35,952	–	–	0.75%	34
2014 Q1	$1.85M	Buy	35,952 +4,340	+14%	+$219K	0.73%	33
2013 Q4	$1.67M	Hold	31,612	–	–	0.67%	37
2013 Q3	$1.41M	Hold	31,612	–	–	0.61%	47
2013 Q2	$1.31M	Buy	+31,612	New	+$1.38M	0.59%	45

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Everence Capital Management's ABBV Position: Q1 2026 in Review

Everence Capital Management held its AbbVie (ABBV) position steady in Q1 2026 at 53,171 shares worth $11.6M. The position accounts for 0.71% of the portfolio, ranked #21.

Everence Capital Management first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $12.3M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Everence Capital Management held 53,171 shares of AbbVie worth $11.6M as of Q1 2026.
Everence Capital Management left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.71% of Everence Capital Management's portfolio in Q1 2026, its #21 holding.
Everence Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Everence Capital Management's AbbVie position peaked at $12.3M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Everence Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.